page header

Webinar Library

Can an early stage pipeline offset the loss of exclusivity for key ulcerative colitis and Crohn’s disease brands in the IBD market?

IMS Health’s Pam Narang, PhD., autoimmune analyst, Disease Insights, shares information about the inflammatory bowel disease (IBD) market focusing on current clinical and commercial market dynamics and opportunities.

To see the webinar,Can an earlystage pipeline offset the loss of exclusivity for key ulcerative colitis and crohn’s disease brands in the IBD market?, please fill out the following form:

 

*Required